Peripheral arterial disease
Drug research and approvals for peripheral arterial disease: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 228 studies of peripheral arterial disease are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 228
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- The Effects of Yoga Practice on Exercise Capacity, Arterial Stiffness, Respiratory Function, Peripheral Muscle…NCT07930221 · Not applicable · Hacettepe University · starts Jul 10, 2025
- Perioperative Limb Oxygenation Monitoring in Patients With CLTINCT07931768 · Not applicable · Belarusian State Medical University · starts Nov 2, 2026
- Construction and Empirical Research of a Risk Prediction Model for Preventing Lower Extremity Arteriosclerosis…NCT07881588 · Not applicable · Second Affiliated Hospital of Nanchang University · starts Apr 15, 2025
- Automated ABPI in Peripheral Arterial Disease a Pilot StudyNCT07850349 · Not reported · Hull University Teaching Hospitals NHS Trust · starts Jun 24, 2026
- Comparison of Clopidogrel-based Antiplatelet Agent Treatment and Aspirin Plus Low Dose Rivaroxaban TherapyNCT07796217 · Phase 4 · Seoul National University Bundang Hospital · starts Nov 15, 2023
- Health for Hungary (H4H) - Longitudinal Collection of Blood Samples and Corresponding DataNCT07743021 · Not reported · Center for Molecular Fingerprinting Research Nonprofit LLC · starts Jul 27, 2021
- IVUS Guidance in BTK InterventionsNCT07731997 · Not applicable · Shin Kong Wu Ho-Su Memorial Hospital · starts Jul 24, 2026
- Evaluation of Proximal Massage and Palm-to-Fist Tapping on Reducing the Risk of PhlebitisNCT07703618 · Not applicable · Hospital Universitario San Ignacio · starts Jun 3, 2025
- Predictors of Major Adverse Limb Events After Endovascular Iliac Stenting: a Real-world Cohort StudyNCT07672249 · Not reported · I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio · starts Jun 16, 2026
Approved 3
- ClopidogrelPurinergic receptor P2Y12 antagonist
- RivaroxabanCoagulation factor X inhibitor
- VorapaxarProteinase-activated receptor 1 antagonist
Phase 3 12 of 16
- AspirinCyclooxygenase inhibitor
- TicagrelorPurinergic receptor P2Y12 negative allosteric modulator
- Carnosine
- CilostazolPhosphodiesterase 3A inhibitor
- SildenafilPhosphodiesterase 5A inhibitor
- MetforminMitochondrial complex I (NADH dehydrogenase) inhibitor
- PaclitaxelTubulin inhibitor
- TiclopidinePurinergic receptor P2Y12 antagonist
- Omega-3-ACID ethyl esters
- DalcetrapibCholesteryl ester transfer protein inhibitor
- SarpogrelateSerotonin 2a (5-HT2a) receptor antagonist
- Sulodexide
Phase 2 12 of 22
- SimvastatinHMG-CoA reductase inhibitor
- Riferminogene pecaplasmid
- Ghrelin
- Nitrous acid
- ValsartanType-1 angiotensin II receptor antagonist
- AlprostadilProstanoid EP1 receptor agonist
- EdoxabanCoagulation factor X inhibitor
- ProbucolATP-binding cassette sub-family A member 1 inhibitor
- TemsirolimusFK506-binding protein 1A inhibitor
- Dexamethasone phosphoric acidGlucocorticoid receptor agonist
- CanakinumabInterleukin-1 beta inhibitor
- SacubitrilNeprilysin inhibitor
Phase 1 or earlier 10
- VonapanitaseElastin proteolytic enzyme
- FilgrastimGranulocyte colony stimulating factor receptor agonist
- InclacumabP-selectin antagonist
- LosartanType-1 angiotensin II receptor antagonist
- NitroglycerinSoluble guanylate cyclase activator
- PioglitazonePeroxisome proliferator-activated receptor gamma agonist
- Edetate disodiumCalcium chelating agent
- ColchicineTubulin inhibitor
- TalfirastideProto-oncogene Mas agonist
- Diroximel fumarateKelch-like ECH-associated protein 1 inhibitor
How its trials ended
1,466 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 330 whose ending is known, 47% met their primary endpoint, 8% missed it and 45% stopped early.
- Completed, result not reported57539%
- Ongoing30521%
- Status unknown25617%
- Met its primary endpoint15411%
- Stopped: other or unclear816%
- Stopped: enrollment or feasibility312%
- Missed its primary endpoint272%
- Stopped: sponsor or business decision191%
- Stopped: lack of efficacy101%
- Stopped: funding81%
| Feb 8, 2021 | Hexasodium salt of myo-inositol hexaphosphate (IP6,…Treatment of peripheral arterial disease in patients with end-stage kidney disease | Vifor Pharma, Inc. | Designated |
| Sep 10, 1996 | Prostaglandin E1 in lipid emulsionTreatment of ischemic ulceration of the lower limbs due to peripheral arterial disease. | Alpha Therapeutic Corporation | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA